PTC Therapeutics, Inc. Revenues
PTC Therapeutics, Inc. (PTCT) reported Revenues of $264.73 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2019-03-01
- PTC Therapeutics, Inc. revenues for fiscal 2018 was $264.73M, a 36.19% increase from fiscal 2017.
- PTC Therapeutics, Inc. revenues for fiscal 2017 was $194.39M.
| Period end | Revenues 12 month |
|---|---|
| 2018-12-31 | $264.73M 10-K · filed 2019-03-01 |
| 2017-12-31 | $194.39M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |